Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 7.01 (Regulation FD Disclosure). European commercialization rights for investigational navenibart granted to Neopharmed Gentili affiliate.
BIOCRYST PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- European commercialization rights for investigational navenibart granted to Neopharmed Gentili affiliate
- $70 million upfront consideration strengthens near-term funding
- Up to $275 million in regulatory and sales milestones creates additional contingent value
- Tiered royalties of 18%–30% on net sales provide recurring European revenue potential
- Partnership reduces BioCryst’s direct European commercialization burden for hereditary angioedema
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOCRYST PHARMACEUTICALS INC 8-K filings
Get the next BCRX 8-K as it lands
Follow BCRX for push alerts, or ask the research agent what this filing means.